]-vasopressin, underwent the same degradation process. Bacitracin prevented degradation at doses äs low äs 40 mg/1 without alterating the binding affinity.
I]Z-Tyr-[Lys

Introduction
Vasopressin stimulates the kidney to concentrate the urine by increasing the water permeability of renal collecting duct epithelial cells (1) . Vasopressin, like other peptide hormones, exerts its physiological function by binding to cell-surface receptors in association with a specific guanine nncleotide-binding protein (2) . These actions in the kidney are mediated by the adenylate cyclase-coupled V 2 -receptor subtype. The lack of highly specific vasopressin radioligands has hampered further progress in vasopressin receptor researefr (e. g. internalization studies on vasopressin, autoradiography and mapping of the renal vasopressin receptor along the nephron). We previously described a new series of iodi-*) Present address: Department of Medicine, Baypines VA Medical Center, Baypines, USA **) Present address: Medizinische Klinik I, Friedricb-Alexander-Universität Erlangen, Erlangen, Germany. nated väsopressin analogues with high specific radioactivity and high afifinity for the vasopressin V] and V 2 isoreceptors (1). But little is known about the degradation of these new receptor ligands. It was therefore the aim of this study 
Materials and Methods
Materials
N-rerr-Butoxycarbonyl-L-tyrosine-hydroxysuccinimidyl ester, N-/Boc-jD-tyrosine, N-hydroxysuccinimidyl ester, and, ', 1 , dicyclocarbodiimide were from Bachern, Heidelberg. Unless otherwise stated, the other reagents were of analytical grade and were purchased from Merck (Darmstadt, Germany) and Sigma (Munich, Germany). We used LLC-PKi cells (a porcine renal tubular cell line, ATCC CRL 1392 
Preparation of crude plasma membrane fractions
Partially purified membranes frorn LLC-PKi cells were prepared s described (4) . Briefly, cells were detached by incubation for 30 min at 37 °C in 50 mmol/l Tris, 0.15 mol/1 NaCl, l g/l Na 2 EDTA, pH 7.4. They were then lysed using a hypotonic buffer (5 mmol/l Tris-HCl, l mmol/l EDTA and 3 mmol/l MgCl 2 , pH 7.4), and finally the lysate was homogenized. The homogenate was centrifuged at 2000 g for 10 min and the pellet thus obtained was washed twice in assay buffer and processed immediately. ]-vasopressin (5 X l O 3 -2 X l O 6 cpm/ tube, which is equivalent to 0.012 nmol/1 -4 nmol/1; the incubation volume was 150 μΐ) for "hot Saturation" studies. Unless othenvise stated, binding studies were performed at 22 °C for 90 min s described previously (3, 4) . Assay buffer for binding studies contained 100 mmol/l Tris, 5 mmol/l MgCl 2 , and lg/1 bovine serum albumin, pH 7.8. Non-specific binding was determined by addition of 3.3 μηιοΐ/ΐ [Lys 8 ]-vasopressin. Gold binding buffer (2 ml) was added. After the Separation of free and bound radioactivity by centrifugation at 3000 g for 10 min t 4 °C, washing was performed twice in cold binding buffer.
Degradation studies
Radioligands were incubated with membrane preparations for 60 *to 90 min at room temperature in 12 X 75 mm polystyrene tubes. Apprpximately l O 5 counts/min of radioligand were incubated with the biological membrane at a final volume of 150 μΐ assay buffer. After centrifugation the incubation mixture at 2000g, the supernatant was directly applied to a RP-HPLC column. In some experiments, l ml of l g/l trifluoroacetic acid was added to the pellet.
The pellet was resuspended and homogenized, and the Suspension was applied to a methanol-activated Sep-Pak C-18 cartridge. The cartridge was then washed with 2 ml lg/1 trifluoroacetic acid. No radioactivity eluted from the Sep-Pak C-18 cartridge during this washing procedure. Radioactivity was then eluted with 0.5 ml methanol. Methanol was evaporated, 150 μΐ lg/1 trifluoroacetic acid was added and the solution was applied to the RP-HPLCcolumn, s described above.
.,
Reversed phase high performance liquid chromatography RP-HPLC was performed with a System from LKB-Pharmacia (Uppsala, Sweden) (HPLC Gradient Pump 2249, Solvent Cpnditioner 2156, Fraction Collector Frac-100) coupled to a UV-Vis Det ector (Variable Wavelength Monitor 2141) and a radioactivity flow through rnonitor (Ramona 90) from RAYTEST Isotopenme ger te GmbH (Straubenhardt, Germany). Analysis and Integration were performed on an Intel 80386 processor-iased Computer using the Nelson-(LKB Pharmacia) or Raytest Software. Peptides were applied to a spherisorb S 5 ODS II column (5 μπι, 250 X 4 mm) from Knauer (Berlin, Germany) and eluted by a gr dient of l g/l trifluoroacetic acid in water (solvent A) and l g/l trifluoroacetic acid in acetonitrile (solvent B, 5-60%) within 60 min (or in 20 min, s specified). The flow rate was l ml/min, and 0.5 ml fractions were collected.
Results and Discussion
Binding of N ]-vasopressin by mercaptoethanol, fig. 2 ), suggesting that the rapid radioligand degradation is mainly due to cleavage of the neighbouring radio- ]-vasopressin can be blocked by enzyme inhibitors, we investigated the influence of bacitracin. After bindî ng of the radioligand to LLC-PKj cell membranes, the supernatants were purified in a Sep-Pak column and analysed by RP-HPLC. Bacitracin completely inhibited degradation at dosages äs low äs 40 mg/1 ( fig. 3 ). Degradation was not prevented completely at concentrations below 40 mg/1; furthermore degradation was not prevented at all by any of the common enzyme inhibitors, such äs aprotinin, bestatin, soybean trypsin inhibitor, EDTA, 1,10-phenanthroline, and 8-hydroxyquinoline. Sulph-hydryl-specific reagents such äs ethylmaleimide and p-toluenesulphonyl fluoride did prevent tracer degradation but also abolished binding of the radioligand (data not shown).
Bacitacin is a well-known broad-spectrum proteinase inhibitor preventing degradation of insulin, endogenous opioids, etc. (6) (7) (8) . The inhibitory effect of bacitracin on degradation was also confirmed in other Systems ]-vasopressin to LLC-PK^ cell membranes -or other radioligands (1,3, 4, 9) -was not affected by bacitracin (data not shown).
